Indraprastha Medical Share Price Target 2026, 2027, 2028, 2029, 2030

Indraprastha Medical share price today

Indraprastha Medical Corporation runs Indraprastha Apollo Hospitals in Sarita Vihar, south Delhi — a tertiary and super-speciality campus that has been one of the capital’s principal private hospitals since the 1990s. The company was incorporated in 1988 as a joint venture between Apollo Hospitals Enterprise and the Government of the National Capital Territory of Delhi, and that ownership structure remains the most distinctive thing about it.

At the 6 August 2026 cut-off the share closed at ₹361.85, giving a reconciled market capitalisation near ₹3,323 crore on trailing EPS of ₹19.99. The quote above moves; everything below is fixed to that session.

Here is the tension in one line. This is a hospital earning a 35.83% return on capital employed, trading at roughly 18 times earnings — and the shares sat about 44% below their 52-week high of ₹640.85, barely above the ₹342 low. The operating results published through FY26 do not, on their own, explain a drawdown of that size.

One hospital, and what that means

Most listed hospital groups are portfolios: a mature flagship funds new units, and the investment case is about the ramp of beds that are not yet profitable. Indraprastha Medical is closer to the opposite. Its economics are dominated by a single large, long-established Delhi campus operating at maturity.

Structural feature	Indraprastha Medical	Investment consequence
Asset base	One principal Delhi campus	No dilution from immature beds, but no internal growth engine either
Operator	Apollo Hospitals Enterprise	Clinical systems, brand and referral network of a national group
Co-owner	Government of NCT of Delhi	Unusual for a listed private hospital; shapes obligations and optics
Land	Provided on concessional terms	Carries public-service obligations attached to the concession
Maturity	Long-established, high occupancy	High returns on a depreciated asset base

That fifth row explains the return ratios. A hospital built decades ago and substantially depreciated will show a high return on capital employed almost mechanically, because the denominator is small. It is a real economic advantage — the cash is genuine — but it is not the same thing as a business that can deploy new capital at 36%. Growth here has to come from pricing, case mix and throughput, not from replicating the asset.

FY26 was a solid year, not a troubled one

The audited year to March 2026 showed total income of about ₹1,511 crore and earnings per share of roughly ₹20.03. The March quarter reported total income near ₹372 crore with net profit around ₹41.7 crore, on revenue growth of roughly 9.3% and an operating margin near 16.6%. The December quarter had shown revenue of about ₹379 crore.

FY26 measure	Reported outcome	Reading
Total income	About ₹1,511 Cr	Steady scale for a single-campus operator
Earnings per share	About ₹20.03	Consistent with the ₹19.99 trailing figure used here
Q4 FY26 total income	About ₹372 Cr	Revenue growth near 9.3% year on year
Q4 FY26 net profit	About ₹41.7 Cr	Roughly ₹167 crore annualised on that quarter alone
Q4 FY26 operating margin	About 16.6%	Below the group-level margins of larger listed peers
Q3 FY26 revenue	About ₹379 Cr	Quarterly revenue is stable rather than volatile

Trailing EPS of ₹19.99 across roughly 9.1843 crore shares implies annual profit near ₹184 crore, which reconciles with the reported FY26 per-share figure. In other words the earnings base underpinning the valuation below is consistent with what the company actually published.

Why the PEG ratio should be ignored here

The data available for this company shows a five-year profit CAGR of about 132%, which produces a PEG of roughly 0.14. We are quoting it because it appears in the standard metric set, and immediately advising that it be disregarded.

The reason is a base effect. Hospitals were among the worst-affected businesses in the pandemic years, and a growth rate measured from a collapsed base produces an arithmetically true and analytically useless number. Nothing about Indraprastha Medical suggests it can compound profit at anything close to triple digits. The five-year sales CAGR of about 19.3% is the more informative figure, and even that is flattered by the same recovery.

Growth measure	Reported value	How much weight it deserves
Five-year profit CAGR	About 132.2%	None — a pandemic base artefact
PEG	About 0.14	None — inherits the same distortion
Five-year sales CAGR	About 19.3%	Some — partly recovery, partly real
FY26 revenue growth	About 9.3% in Q4	The most honest recent indicator

Our scenario assumptions below are built off that last row, not the first two. A base case of 13% earnings growth for a mature single-campus hospital is an assumption about pricing, case mix and modest throughput gains, not about repeating a recovery that has already happened.

The obligations attached to the land

The land on which the hospital operates was provided by the Delhi government on concessional terms, and that concession carries obligations to provide free treatment to economically weaker patients. The scope and enforcement of those obligations have been the subject of long-running litigation and periodic public scrutiny. We are not in a position to predict how that resolves, and we would be sceptical of anyone who claims to be.

What can be said is structural. A cost obligation of this kind sits between the company and its margin, it is set by courts and government rather than by management, and it does not shrink as the business grows. That is a permanent feature of the investment case rather than a passing risk, and it is one reasonable explanation for why this asset trades at a discount to the multiples carried by listed hospital groups without a comparable arrangement.

The drawdown we cannot fully explain

The shares fell from ₹640.85 to ₹361.85 over the 52 weeks to the cut-off, a decline of about 44%, ending close to the period low of ₹342. Over the same broad period the company reported growing revenue and healthy profitability.

We have not found, in the disclosures and coverage available to us, a single operating development that accounts for a fall of that magnitude. That is worth stating plainly rather than papering over with a plausible narrative. Possible contributors include a de-rating of the whole small-cap healthcare cohort after a strong run, market discounting of the free-treatment obligations, the structural limits of a single-asset operator, or simply the unwinding of a valuation that had become stretched at ₹640. An investor should treat the gap between the operating record and the price action as an open question, and should size the position on the assumption that the market may know something the filings have not yet made obvious.

Valuation at the fixed price

At ₹361.85 the shares traded at about 18.1 times trailing earnings and 4.5 times book, with a dividend yield near 1.11%.

Valuation metric	6 August 2026 value	Basis
Share price	₹361.85	Exchange close on the cut-off date
Reconciled market capitalisation	₹3,323 Cr	Price times about 9.1843 crore shares
Recalculated P/E	18.10×	₹361.85 divided by trailing EPS of ₹19.99
Recalculated price to book	4.48×	₹361.85 divided by ₹80.70 book value per share
Dividend yield	About 1.11%	On roughly ₹4.01 per share
Return on capital employed	35.83%	Against a five-year average of 35.35%
52-week range	₹342.00 – ₹640.85	Cut-off price about 44% below the high

Note that unlike most companies in this batch, current ROCE of 35.83% is slightly above the five-year average of 35.35%. The operating engine has not deteriorated. Whatever drove the share price down, the returns on capital did not move with it.

The valuation fields available were captured on a different day from the price we fixed, so market capitalisation and all per-share ratios above were recomputed against the ₹361.85 close and roughly 9.1843 crore shares.

Valuation framework: a mature asset, modestly grown

The scenario model compounds trailing EPS of ₹19.99 from the cut-off, applying 147/365 of a year’s growth to the 2026 row and one further full year to each subsequent row, then an exit price-to-earnings multiple. Values round to the nearest ₹5 and exclude dividends.

Scenario	Annual EPS growth	Exit P/E	Operating interpretation
Bear	8%	14×	Free-treatment costs rise, single-asset limits bind, discount persists
Base	13%	19×	Pricing and case mix improve steadily and the multiple partly recovers
Bull	18%	24×	Obligations clarify favourably and the market re-rates toward peer levels

The bull case deliberately does not assume new hospitals. It assumes the existing campus is valued closer to what a 36% return on capital would normally command once the overhangs are better understood.

Indraprastha Medical share price target 2026 to 2030

The grid above resolves those assumptions into yearly values. As with every scenario table on this site, the exit multiple does most of the work in the later years, which is why the assumptions travel with the numbers.

What would change the thesis

The case strengthens if the free-treatment obligations are settled in a way that makes the annual cost quantifiable, if revenue growth holds near or above 10% with margin stable, if capacity or case-mix initiatives at the Delhi campus lift throughput, and if the dividend continues to rise alongside earnings.

It weakens if the obligations expand or the associated liabilities crystallise, if operating margin drifts below the mid-teens, if the single-asset concentration is exposed by a competitive new facility in south Delhi, or if the ownership structure produces decisions that favour objectives other than shareholder returns.

Quarterly monitoring scorecard

Question	Constructive evidence	Warning sign
Is revenue still compounding?	Growth sustained near or above 10%	Growth slips to low single digits
Is margin holding?	Operating margin stable near 16–17%	Sustained compression below 14%
Are obligations quantified?	Disclosure puts a number on the annual cost	Contingent liabilities grow without explanation
Is capital still productive?	ROCE stays above the 35.35% five-year mean	Return ratios fall with rising capital employed
Is the payout intact?	Dividend rises with earnings	Payout cut without a stated reinvestment plan
Does the discount narrow?	Multiple recovers as clarity improves	Discount widens on unchanged fundamentals

What to weigh at the current price

The straightforward reading is that an investor is being offered a mature, cash-generative, Apollo-operated Delhi hospital at roughly 18 times earnings and 4.5 times book, after a 44% fall that the operating numbers do not explain, with return on capital still running slightly above its own five-year average.

The complication is that single-asset businesses have no second engine, the free treatment obligations are set by parties other than management, and the market has been marking this down for a year for reasons we cannot fully evidence. Our own judgement is that the price now compensates for those known structural features. That judgement is explicitly weaker than it would be for a company where the drawdown had a documented operating cause, and readers should treat the unexplained gap as the main reason to size the position conservatively rather than as a reason to dismiss it.

FAQ

What is the Indraprastha Medical share price target for 2030?

The grid above gives bear, base and bull values from trailing EPS, a growth assumption and an exit multiple. The bear case assumes the current discount persists; the bull assumes it narrows toward hospital-sector norms.

Is Indraprastha Medical the same as Apollo Hospitals?

No. It is a separate listed company, formed as a joint venture between Apollo Hospitals and the Delhi government, which operates the Indraprastha Apollo campus in south Delhi.

Why is the PEG ratio so low?

Because the five-year profit CAGR of roughly 132% is measured from a pandemic base when hospital earnings had collapsed. The resulting PEG near 0.14 is arithmetically correct and analytically meaningless.

Why has the share price fallen so far from its high?

The shares fell about 44% from ₹640.85 over 52 weeks while the company kept reporting growth. We cannot identify a single operating cause in the available disclosures, which is itself a reason for caution.

What is the biggest risk in Indraprastha Medical shares?

Concentration in one hospital, combined with free-treatment obligations attached to the concessional land whose scope is set by courts and government rather than by management.

When does Indraprastha Medical report its next result?

Check the results calendar and confirm the board-meeting date from the company’s own exchange filing before relying on any estimate.

Related research

• Apollo Hospitals share price target
• Rainbow Childrens Medicare share price target
• Kovai Medical share price target

Sources and methodology

• Indraprastha Medical Corporation on Screener
• Indraprastha Medical Q4 FY26 results
• Indraprastha Medical Q4 FY26 summary
• Indraprastha Medical Q3 FY26 revenue report
• Indraprastha Medical quarterly results history

Return and margin metrics are Screener figures captured on 6 August 2026, with price and the 52-week range from exchange closing data for the same session; all per-share ratios were recomputed against that single price. FY26 and quarterly figures are as reported by the company and contemporaneous coverage. The scope of the free-treatment obligations is described qualitatively because we could not verify a current quantified position, and the unexplained share-price drawdown is reported as unexplained rather than attributed to a cause we cannot evidence. The dividend was revised on a later cross-check: our batch data implied about ₹4.48 per share, while Screener’s published yield implies roughly ₹4.01, and we have used the lower, source-corroborated figure. Promoters — Apollo Hospitals Enterprise together with the Delhi government — held about 51.00% as of June 2026.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. Price targets are scenario arithmetic, not promises. Verify current filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.